Meeting
2021 ASCO Annual Meeting
Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIVaggressive breast cancer.
Authors
Paolo D'Amico
Northwestern University, Feinberg School of Medicine, Chicago, IL
Paolo D'Amico , Carolina Reduzzi , Sara Gandini , Lorenzo Gerratana , Wenan Qiang , Qiang Zhang , Frederique St-Pierre , Youbin Zhang , Ami N. Shah , Andrew A. Davis , Saya Jacob , Elena Vagia , Firas Hazem Wehbe , Amir Behdad , Giuseppe Curigliano , Massimo Cristofanilli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3036)
DOI
10.1200/JCO.2021.39.15_suppl.3036
Abstract #
3036
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Long-term follow up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and HER2-targeting systemic therapy (HER2-Tx) for HER2+ metastatic breast cancer (MBC).
First Author: Giuseppe Gullo
Poster
2014 ASCO Annual Meeting
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.
First Author: Rachel A. Freedman
Poster
2024 ASCO Breakthrough
Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.
First Author: Xingliang Tan
First Author: Nicholas Patrick McAndrew